GOLDEN BIOTECHNOLOGY CORPORATION Financials Golden Biotechnology Corporation
Equities
4132
TW0004132006
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.95 TWD | +4.56% |
|
-1.29% | -41.53% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 3,237 | 3,874 | 6,459 | 17,123 | 8,548 | 5,582 |
| Enterprise Value (EV) 1 | 3,115 | 3,948 | 6,285 | 16,685 | 8,309 | 5,643 |
| P/E ratio | -9.27 x | -13.5 x | -15.7 x | -38.7 x | -31.4 x | -15.4 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 35.5 x | 46.5 x | 72.7 x | 209 x | 39.2 x | 88 x |
| EV / Revenue | 34.1 x | 47.4 x | 70.8 x | 204 x | 38.1 x | 89 x |
| EV / EBITDA | -10.8 x | -17.6 x | -20.4 x | -43.2 x | -32.2 x | -17 x |
| EV / FCF | -15.6 x | -49.4 x | -36.7 x | -126 x | -84.1 x | -36.8 x |
| FCF Yield | -6.42% | -2.03% | -2.72% | -0.8% | -1.19% | -2.71% |
| Price to Book | 3.6 x | 5.68 x | 7.34 x | 17.8 x | 11.2 x | 13.9 x |
| Nbr of stocks (in thousands) | 114,032 | 115,757 | 132,227 | 132,227 | 142,227 | 142,227 |
| Reference price 2 | 28.39 | 33.47 | 48.85 | 129.5 | 60.10 | 39.25 |
| Announcement Date | 11/04/19 | 01/04/20 | 30/03/21 | 28/04/22 | 28/04/23 | 29/04/24 |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 91.28 | 83.29 | 88.82 | 81.77 | 217.8 | 63.43 |
| EBITDA 1 | -289 | -224.3 | -307.8 | -386.2 | -258.2 | -331.4 |
| EBIT 1 | -334.6 | -270.5 | -347.9 | -423.8 | -296.8 | -365.6 |
| Operating Margin | -366.52% | -324.71% | -391.71% | -518.35% | -136.24% | -576.36% |
| Earnings before Tax (EBT) 1 | -343.7 | -285 | -388.8 | -441.5 | -271.8 | -361.3 |
| Net income 1 | -343.8 | -285.1 | -391.4 | -443.8 | -271.9 | -361.6 |
| Net margin | -376.6% | -342.31% | -440.61% | -542.8% | -124.81% | -570.15% |
| EPS 2 | -3.063 | -2.480 | -3.114 | -3.350 | -1.912 | -2.543 |
| Free Cash Flow 1 | -199.8 | -79.98 | -171.1 | -132.7 | -98.85 | -153.2 |
| FCF margin | -218.9% | -96.02% | -192.59% | -162.24% | -45.38% | -241.53% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 11/04/19 | 01/04/20 | 30/03/21 | 28/04/22 | 28/04/23 | 29/04/24 |
1TWD in Million2TWD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | 73.8 | - | - | - | 61 |
| Net Cash position 1 | 123 | - | 174 | 438 | 239 | - |
| Leverage (Debt/EBITDA) | - | -0.3289 x | - | - | - | -0.1842 x |
| Free Cash Flow 1 | -200 | -80 | -171 | -133 | -98.8 | -153 |
| ROE (net income / shareholders' equity) | -33% | -36.1% | -50.1% | -46.3% | -30.2% | -62% |
| ROA (Net income/ Total Assets) | -16.6% | -16.1% | -20.1% | -19.8% | -14.3% | -25.1% |
| Assets 1 | 2,071 | 1,770 | 1,945 | 2,239 | 1,899 | 1,438 |
| Book Value Per Share 2 | 7.890 | 5.900 | 6.660 | 7.280 | 5.380 | 2.830 |
| Cash Flow per Share 2 | 2.170 | 1.190 | 3.240 | 5.140 | 3.680 | 1.480 |
| Capex 1 | 34.9 | 10.9 | 11.5 | 9.34 | 14.4 | 4.89 |
| Capex / Sales | 38.25% | 13.08% | 12.97% | 11.43% | 6.61% | 7.7% |
| Announcement Date | 11/04/19 | 01/04/20 | 30/03/21 | 28/04/22 | 28/04/23 | 29/04/24 |
1TWD in Million2TWD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -41.53% | 100M | |
| +16.45% | 122B | |
| +21.96% | 116B | |
| +23.73% | 27.03B | |
| -20.05% | 20.36B | |
| -16.28% | 15.91B | |
| -16.52% | 16.43B | |
| -44.35% | 15.6B | |
| +63.91% | 14.94B | |
| +2.52% | 13.59B |
- Stock Market
- Equities
- 4132 Stock
- Financials Golden Biotechnology Corporation
